The approval is based on subgroup analysis of the Phase 3 PROpel trial evaluating Lynparza + Abiraterone and prednisone or prednisolone in patients with BRCA mutated mCRPC

• Lynparza + abiraterone demonstrated highly clinically meaningful improvements in both radiographic progression-free survival and overall survival

• Median rPFS and median OS were not reached for Lynparza + abiraterone vs the median of 8 months and 23 months respectively for abiraterone alone

• Safety of the combination was in line with that observed in prior clinical trials